Core Viewpoint - Anixa Biosciences has announced the issuance of a key patent for its ovarian cancer vaccine technology, which is expected to enhance the company's position in the cancer treatment market [1][4]. Group 1: Patent and Technology - The United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025, covering methods related to eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2) [1]. - The patent includes methods for administering an immunogenic composition that encodes the AMHR2 polypeptide, specifically targeting the extracellular domain of human AMHR2 [3]. - Anixa holds exclusive worldwide rights to the patent, which was issued to Cleveland Clinic [3]. Group 2: Collaboration and Development - The ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations such as those with BRCA mutations [2]. - Anixa's therapeutic portfolio includes an ovarian cancer immunotherapy program utilizing chimeric endocrine receptor-T cell (CER-T) technology, which is distinct from traditional CAR-T therapies [4]. - The company is also developing additional cancer vaccines in collaboration with Cleveland Clinic to address various cancers, including breast, lung, colon, and prostate cancers [4].

Core Insights - Anixa Biosciences has received a Notice of Allowance from the USPTO for a key patent application related to its ovarian cancer vaccine technology, which targets Anti-Mullerian Hormone Receptor, Type II (AMHR2) [1][4] - The ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations such as those with BRCA mutations [2] - The allowed claims cover methods of administering an immunogenic composition that elicits an AMHR2-specific immune response [3] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a focus on ovarian cancer immunotherapy and a unique CAR-T technology [4] - The company collaborates with renowned research institutions to develop vaccines for various cancers, including breast, lung, colon, and prostate cancers, targeting "retired" proteins expressed in these malignancies [4] - Anixa's business model emphasizes partnerships at all stages of development, allowing for the exploration of emerging technologies for commercialization [4]